- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01503112
Predicting Response to Incretin Based Agents in Type 2 Diabetes (PRIBA)
Does Urinary C-peptide Creatinine Ratio Predict Response to Incretin Based Agents in Type 2 Diabetes
Type 2 diabetes is a major and rapidly increasing health problem worldwide. Keeping the blood glucose (sugar) from going too high helps prevent complications. Recently a number of new treatments (collectively called 'incretin based' treatments) to lower blood glucose have become available but response is very variable and it is difficult to predict which will work for an individual. The investigators want to see if we can identify whether the new treatments are likely to be effective for an individual patient. Identifying the right treatment would improve control and minimise the side-effects and costs from ineffective treatments. We will collect blood (for measures of blood glucose, insulin secretion and genetics information), urine (for a simple measurement of insulin secretion) and other clinical information (such as weight,age, duration of diabetes and medication) in people who are about to start these new 'incretin based' treatments and assess their response over the first 6 months of treatment. We will analyse this information to see if we can predict treatment response.
Study Hypothesis:
The investigators hypothesise that those who have low insulin secretion, as measured by post meal urine C-peptide Creatinine Ratio or blood C-peptide, will have poor blood glucose response to incretin based treatments.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Bournmouth, Det Forenede Kongerige, BH7 7DW
- The Royal Bournmouth and Christchurch Hospitals NHS Trust
-
Bristol, Det Forenede Kongerige, BS10 5NB
- North Bristol NHS Trust
-
Ipswich, Det Forenede Kongerige, IP4 5PD
- Ipswich Hospital NHS Trust
-
Northampton, Det Forenede Kongerige, NN15BD
- Northampton General Hospital NHS Trust
-
Oxford, Det Forenede Kongerige, OX3 9DU
- Oxford Radcliffe Hospitals NHS Trust
-
Portsmouth, Det Forenede Kongerige, PO6 3LY
- Portsmouth Hospitals NHS Trust
-
Redhill, Det Forenede Kongerige, RH1 5RH
- Surrey and Sussex Healthcare NHS Trust
-
St Leonards-on-Sea, Det Forenede Kongerige, TN37 7RD
- East Sussex Healthcare Nhs Trust
-
Stoke on Trent, Det Forenede Kongerige, ST4 7LN
- University Hospitls North Staffordshire NHS Trust
-
Warwick, Det Forenede Kongerige, CV34 5BW
- South Warwickshire NHS Foundation Trust
-
Watford, Det Forenede Kongerige, WD18 0HB
- West Hertfordshire Hospitals NHS Trust
-
-
Cornwall
-
Truro, Cornwall, Det Forenede Kongerige, TR13HD
- Cornwall and Isles of Scilly NHS Primary Care Trust
-
-
Devon
-
Barnstaple, Devon, Det Forenede Kongerige, EX314JB
- North Devon NHS Trust
-
Exeter, Devon, Det Forenede Kongerige, EX25DW
- Royal Devon and Exeter NHS Foundation Trust
-
Plymouth, Devon, Det Forenede Kongerige, PL68DH
- Plymouth Hospitals NHS Trust
-
Torbay, Devon, Det Forenede Kongerige, TQ27AA
- South Devon Healthcare NHS Foundation Trust
-
-
Somerset
-
Taunton, Somerset, Det Forenede Kongerige, BA228HR
- Taunton and Somerset NHS Foundation Trust.
-
Yeovil, Somerset, Det Forenede Kongerige, BA21 4AT
- Yeovil Disctrict Hospital NHS Foundation Trust
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- A clinical diagnosis of type 2 diabetes mellitus where the patient's clinician has determined the need for a DPP-IV inhibitor or GLP-1 analogue as a result of inadequate glycaemic control
- HbA1c >= 58mmol/mol
Exclusion Criteria:
- Treatment with DPP-IV inhibitors or GLP-1 analogues prior to study initiation (within the previous 3 months)
- Renal failure as shown by a eGFR (estimated glomerular filtration rate) less than 30 mL/min/1.73m2
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
Patients starting incretin treatments
Patients starting GLP-1 agonists or DPPIV inhibitors as part of their normal clinical care.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Glycaemic response (HbA1c change post treatment)
Tidsramme: 6 months
|
Change in HbA1c over 6 months treatment (as a continuous variable and/or defined as binary response/non response).
Our Primary analysis will be the relationship between insulin secretion (as measured by blood C-peptide or UCPCR) and glycaemic response.
Secondary analysis will include examination of relationship between baseline weight, HbA1c, age, duration of diabetes, HOMA B, HOMA IR, autoantibody (GAD, IA2) status and glycaemic response.
We will also examine the relationship between glycaemic response and polymorphisms in GLP-1R, TCF7L2, WFS1 and FOX01 genes.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Weight change over 6 months treatment
Tidsramme: 6 months
|
6 months
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studieleder: Andrew T Hattersley, University of Exeter Medical School/Royal Devon and Exeter Hospital NHS Foundation Trust
- Ledende efterforsker: Angus Jones, University of Exeter Medical School/Royal Devon and Exeter Hospital NHS Foundation Trust
Publikationer og nyttige links
Generelle publikationer
- Jones AG, McDonald TJ, Shields BM, Hill AV, Hyde CJ, Knight BA, Hattersley AT; PRIBA Study Group. Markers of beta-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care. 2016 Feb;39(2):250-7. doi: 10.2337/dc15-0258. Epub 2015 Aug 4.
- Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, Weedon MN, Henley WE, Sattar N, Holman RR, Pearson ER, Hattersley AT, Jones AG; MASTERMIND Consortium. Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care. 2018 Apr;41(4):705-712. doi: 10.2337/dc17-1827. Epub 2018 Jan 31.
- Jones AG, Shields BM, Hyde CJ, Henley WE, Hattersley AT. Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine. PLoS One. 2014 Oct 23;9(10):e111235. doi: 10.1371/journal.pone.0111235. eCollection 2014.
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 11233581
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type 2 diabetes
-
Nadir Hastalıkları Araştırma DerneğiRekrutteringNeuronal Ceroid Lipofuxinosis Type2 (CLN2)Kalkun
-
Trabzon Arakli Bayram Halil Public HospitalRekrutteringType2-diabetes, SGLT2-hæmmer, urinvejsinfektionKalkun
-
Alexandra Kautzky-WillerBayerRekrutteringFed lever | Hypogonadisme, mand | Overvægt/fedme | Prædiabetes/Type2 Diabetes MellitusØstrig
-
National Human Genome Research Institute (NHGRI)AfsluttetGeneraliseret arteriel forkalkning af spædbørn | Autosomal recessiv hypophosphatæmisk rakitt type2Forenede Stater
Kliniske forsøg med Ingen intervention, observationsundersøgelse
-
Clinical Research Centre, MalaysiaHospital Queen Elizabeth, MalaysiaAfsluttetCovid19 | Kritisk sygMalaysia
-
Seoul National University HospitalDong-A ST Co., Ltd.Ikke rekrutterer endnuCOVID-19Korea, Republikken